<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294253</url>
  </required_header>
  <id_info>
    <org_study_id>6999</org_study_id>
    <nct_id>NCT02294253</nct_id>
  </id_info>
  <brief_title>Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone</brief_title>
  <official_title>Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone: An Outpatient Detoxification for Opioid Dependence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will randomize 50 opioid-dependent participants who have initially failed
      outpatient induction onto XR-NTX; participants will receive buprenorphine/naloxone on a
      weekly basis for 30 days. Buprenorphine/naloxone will be dispensed weekly during the 30-day
      stabilization and twice weekly during taper phase, and all patients who successfully complete
      the detoxification will be offered induction onto XR-NTX. All participants will receive
      weekly therapy with a study psychiatrist. All participants will receive open-label
      medication. The primary outcome of this study will be percentage of patients successfully
      inducted onto XR-NTX. Secondary outcomes will be time to relapse, defined as opioid use or
      dropout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine induction/stabilization/taper: Buprenorphine induction will be conducted at our
      STARS clinic and according to current clinical guidelines. Participants who have initially
      failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly
      basis that they will take daily, according to the following schedule: 8/2 mg (Days 1-10),
      6/1.5 mg (Days 11-15), 4/1 mg (Days 16-20), 3.0/0.75 mg (Days 21-25), 2.0/0.5 mg (Days
      26-30).

      Participants will attend the clinic twice weekly and will be assessed for opioid and other
      substance use (urine toxicology and self-report), vital signs, opioid withdrawal symptoms,
      opioid cravings, and dose adjustments of buprenorphine will be made as needed by study
      physicians. If a dose reduction is needed, the stabilization and taper schedule will be
      adjusted to occur over 30 days.

      Participants will be stabilized on, and tapered off, buprenorphine over a 4-week
      period.Reductions will occur in a graded fashion, with the stabilization dose reduced to 2
      mg. This approach to buprenorphine taper is intended to resemble standard clinical practice,
      in which patients seeking transition off buprenorphine undergo a slow taper. A gradual taper
      over approximately 4 weeks has established precedent (Sigmon et al. 2013, Ling et al. 2009,
      Nielsen et al. 2013) as a well-tolerated taper strategy for transitioning off buprenorphine.
      The purpose is in part to provide a slow transition with minimal withdrawal symptoms.
      Participants will have at least two study visits a week during the buprenorphine taper, but
      may be seen more regularly at STARS if deemed clinically necessary.

      Naltrexone induction procedure: Participants who successfully complete the taper must then
      complete a two-day washout (abstinence for opioids, buprenorphine). During this 48-hr
      period,participants will report to the STARS clinic daily for vital sign monitoring and to
      receive ancillary medications (clonidine, clonazepam, zolpidem, prochlorperazine) to
      alleviate withdrawal and discomfort as needed. After abstinence of &gt;/=48 hours from the last
      buprenorphine dose, to allow for mu receptor availability, participants will begin the
      naltrexone induction,using a 4-day ascending taper of oral naltrexone (1, 3, 12, and 25 mg),
      followed by injection naltrexone . The administration of naltrexone will occur within a
      detoxification suite provided at STARS, consisting of a private room outfitted with two
      comfortable reclining lounge chairs for resting, adjustable lighting, and an entertainment
      system. Participants will be monitored by clinical staff at least every 1-2 hours with
      frequent vital signs checks and withdrawal assessments. A research psychiatrist or study
      physician will be present at all times to conduct frequent clinical assessments and provide
      adjuvant medications and naltrexone. Patients will be monitored on a daily basis (Monday to
      Friday) for up to 8 hours per day. Transportation home by car service will be provided at the
      end of the day for any patient deemed to have this clinical need.

      On Day 1 of the naltrexone induction,participants are pre-treated with prochlorperazine 10 mg
      for nausea, followed be the first dose of naltrexone 1mg. Ascending doses of naltrexone will
      then be titrated upward slowly (3mg, 12mg, 25mg). Adjuvant medications will be available to
      patients and will include clonidine for myalgias, prochlorperazine for nausea, clonazepam to
      reduce anxiety and dysphoria, and trazodone or zolpidem for insomnia. Participants will be
      provided take-home doses of adjuvant medications in small doses and on a tapering schedule
      for one week post-administration of XR-NTX. Participants will be required to visit the clinic
      daily and remain there for at least 1 hour to permit close monitoring, with an option to stay
      as long as necessary to achieve relief of symptoms and medical stability prior to being
      discharged home.

      Once 25 mg of naltrexone has been tolerated, the participant may receive 380 mg IM XR-NTX.

      Additionally, for female participants, a urine pregnancy test will be obtained on the day of
      XR-NTX administration. Prior to administration of XR-NTX, participants who have been
      non-compliant with the oral naltrexone schedule, accompanied by lapses to opioid use, or in
      any case for which the challenge appears clinically indicated in the judgment of the study
      physician or research team, will receive a naloxone challenge prior to XR-NTX administration.
      Referrals to local treatment providers will be arranged for participants who successfully
      complete the study and request to continue XR-NTX maintenance

      XR-NTX injections: XR-NTX will be administered once naltrexone 25 mg has been tolerated, as
      an intramuscular injection (380 mg) in one buttock by one of the research psychiatrists or
      research nurses of STARS, who are currently trained and administer XR-NTX in other protocols.
      Participants will be observed for at least 2 hours after the first injection. Participants
      will be offered a second injection at Week 5 (four weeks post-administration of the first
      injection), and a third injection at Week 9. Prior to receiving second and third injections
      at STARS, patients will either provide an opioid-negative urine or pass a naloxone challenge
      test.

      At each STARS visit the patient meets with the research assistant to complete research
      ratings, including self-report of withdrawal, mood, and drug use. Blood samples are drawn
      according to the protocol for naltrexone serum levels and liver enzymes. The patient provides
      a urine sample under observation by a staff member at each visit. STARS is staffed by both
      male and female research assistants so that all urines can be appropriately monitored.

      All participants will receive a weekly medication adherence-focused psychosocial intervention
      informed by relapse prevention strategies we previously developed in Behavioral Naltrexone
      Therapy and delivered by the study physician (Rothenberg, Sullivan et al. 2002). We have
      developed a relapse prevention approach which includes an emphasis on compliance with NTX.
      Participants will receive this therapy during weekly visits in outpatient Weeks 1-12
      following induction onto XR-NTX.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Induction Onto XR-NTX</measure>
    <time_frame>One week after completing 30-day buprenorphone/naloxone stabilization/taper.</time_frame>
    <description>Proportion of participants inducted onto XR-NTX at the end of the 30-day buprenorphine/naloxone stabilization/taper.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Buprenorphine/naloxone stabilization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>30 day oral Buprenorphine/naloxone</description>
    <arm_group_label>Buprenorphine/naloxone stabilization</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-60.

          2. Meets DSM-IV criteria for current opiate dependence disorder of at least six months
             duration, supported by urine toxicology OR COWS score &gt; or =6 OR Naloxone Challenge.

          3. Voluntarily seeking treatment for opioid dependence.

          4. In otherwise good health based on complete medical history and physical examination.

          5. Able to give written informed consent.

          6. Failed outpatient induction onto XR-NTX in Protocol #6374.

        Exclusion Criteria:

          1. Methadone maintenance treatment or regular use of illicit methadone (&gt; 30 mg per
             week).

          2. Maintenance on, or regular use of, buprenorphine or other long-acting opioid agonists.

        3.) Pregnancy, lactation, or failure in a sexually active woman to use adequate
        contraceptive methods. 4) Active medical illness which might make participation hazardous,
        such as untreated hypertension, acute hepatitis with AST or ALT &gt; 3 times normal, AIDS,
        unstable diabetes.

        5) Active psychiatric disorder which might interfere with participation or make
        participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder, severe
        Major Depressive Disorder, or suicide risk or 1 or more suicide attempts within the past
        year.

        6) Physiologically dependent on alcohol or sedative-hypnotics with impending withdrawal.
        Other substance use diagnoses are not exclusionary.

        7) History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone,
        clonidine, or clonazepam.

        8) Chronic organic mental disorder (e.g. AIDS dementia). 9) History of accidental drug
        overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or
        incapacitation, whether or not medical treatment was sought or received.

        10) Painful medical condition that requires ongoing opioid analgesia or anticipated surgery
        necessitating opioid medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Evans, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>January 31, 2020</results_first_submitted>
  <results_first_submitted_qc>March 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2020</results_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Adam Bisaga</investigator_full_name>
    <investigator_title>Professor in Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02294253/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02294253/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine/Naloxone Stabilization</title>
          <description>Participants who have initially failedoutpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
Buprenorphine/naloxone: 30 day oral Buprenorphine/naloxone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine/Naloxone Stabilization</title>
          <description>Participants who have initially failedoutpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
Buprenorphine/naloxone: 30 day oral Buprenorphine/naloxone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Induction Onto XR-NTX</title>
        <description>Proportion of participants inducted onto XR-NTX at the end of the 30-day buprenorphine/naloxone stabilization/taper.</description>
        <time_frame>One week after completing 30-day buprenorphone/naloxone stabilization/taper.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine/Naloxone Stabilization</title>
            <description>Participants who have initially failedoutpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
Buprenorphine/naloxone: 30 day oral Buprenorphine/naloxone</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Induction Onto XR-NTX</title>
          <description>Proportion of participants inducted onto XR-NTX at the end of the 30-day buprenorphine/naloxone stabilization/taper.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs will be collected at each visit for the overall duration of the study which up to 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine/Naloxone Stabilization</title>
          <description>Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
Buprenorphine/naloxone: 30 day oral Buprenorphine/naloxone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased energy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Bisaga MD</name_or_title>
      <organization>NYS Psychiatric Institute</organization>
      <phone>646-774-6155</phone>
      <email>adam.bisaga@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

